These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease. Hamad Z; Aljedai A; Halwani R; AlSultan A Ann Saudi Med; 2013; 33(4):372-6. PubMed ID: 24060717 [TBL] [Abstract][Full Text] [Related]
11. Heme oxygenase-1 promoter polymorphisms and neonatal jaundice. Kaplan M; Renbaum P; Hammerman C; Vreman HJ; Wong RJ; Stevenson DK Neonatology; 2014; 106(4):323-9. PubMed ID: 25277974 [TBL] [Abstract][Full Text] [Related]
12. Co-inheritance of G6PD deficiency and 211 G to a variation of UGT1A1 in neonates with hyperbilirubinemia in eastern Guangdong. Xu JX; Lin F; Chen ZK; Luo ZY; Zhan XF; Wu JR; Ma YB; Li JD; Yang LY BMC Pediatr; 2021 Dec; 21(1):564. PubMed ID: 34895177 [TBL] [Abstract][Full Text] [Related]
13. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. Toffoli G; Cecchin E; Corona G; Russo A; Buonadonna A; D'Andrea M; Pasetto LM; Pessa S; Errante D; De Pangher V; Giusto M; Medici M; Gaion F; Sandri P; Galligioni E; Bonura S; Boccalon M; Biason P; Frustaci S J Clin Oncol; 2006 Jul; 24(19):3061-8. PubMed ID: 16809730 [TBL] [Abstract][Full Text] [Related]
14. UGT1A1*28 gene polymorphism was not associated with the risk of neonatal hyperbilirubinemia: a meta-analysis. Li H; Zhang P J Matern Fetal Neonatal Med; 2021 Dec; 34(24):4064-4071. PubMed ID: 31818155 [TBL] [Abstract][Full Text] [Related]
15. Glucose-6-phosphate dehydrogenase (G6PD) mutations and UDP-glucuronosyltransferase promoter polymorphism among G6PD deficient Kuwaitis. Samilchuk E; Al-Suliman I; Usanga E; Al Awadi S Blood Cells Mol Dis; 2003; 31(2):201-5. PubMed ID: 12972027 [TBL] [Abstract][Full Text] [Related]
16. Serum bilirubin concentration in healthy adult North-Europeans is strictly controlled by the UGT1A1 TA-repeat variants. Kringen MK; Piehler AP; Grimholt RM; Opdal MS; Haug KB; Urdal P PLoS One; 2014; 9(2):e90248. PubMed ID: 24587300 [TBL] [Abstract][Full Text] [Related]
17. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238 [TBL] [Abstract][Full Text] [Related]
18. The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients. AlFadhli S; Al-Jafer H; Hadi M; Al-Mutairi M; Nizam R PLoS One; 2013; 8(10):e77681. PubMed ID: 24204915 [TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of UGT1A1 Genetic Analysis in Chinese Neonates with Severe Hyperbilirubinemia. Yang H; Wang Q; Zheng L; Zheng XB; Lin M; Zhan XF; Yang LY Pediatr Neonatol; 2016 Aug; 57(4):310-7. PubMed ID: 26727668 [TBL] [Abstract][Full Text] [Related]
20. (TA)n UGT 1A1 promoter polymorphism: a crucial factor in the pathophysiology of jaundice in G-6-PD deficient neonates. Kaplan M; Renbaum P; Vreman HJ; Wong RJ; Levy-Lahad E; Hammerman C; Stevenson DK Pediatr Res; 2007 Jun; 61(6):727-31. PubMed ID: 17426648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]